Rational development of 4-aminopyridyl-based inhibitors targeting trypanosoma cruzi CYP51 as anti-chagas agents

Journal of Medicinal Chemistry

Volumn 56, Issue 19, 2013, Pages 7651-7668

  Choi, Jun Yong ^a   Calvet, Claudia M ^b,c,d   Gunatilleke, Shamila S ^b,c,e   Ruiz, Claudia ^a   Cameron, Michael D ^a   McKerrow, James H ^b,c   Podust, Larissa M ^b,c   Roush, William R ^a  

^a Scripps Florida ^*  (United States)

^b University of California at San Francisco   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e SEATTLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPROTOZOAL AGENT; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; N [3 (1H INDOL 3 YL) 1 OXO 1 (PYRIDIN 4 YLAMINO)PROPAN 2 YL] 2 DIFLUORO 4 MORPHOLINOBENZAMIDE; N [3 (1H INDOL 3 YL) 1 OXO 1 (PYRIDIN 4 YLAMINO)PROPAN 2 YL] 2 FLUORO 4 [4 (4 FLUOROBENZYL)PIPERAZIN 1 YL]BENZAMIDE; N [3 (1H INDOL 3 YL) 1 OXO 1 (PYRIDIN 4 YLAMINO)PROPAN 2 YL] 2 FLUORO 4 [4 (PHENYLSULFONYL)PIPERAZIN 1 YL]BENZAMIDE; N [3 (1H INDOL 3 YL) 1 OXO 1 (PYRIDIN 4 YLAMINO)PROPAN 2 YL] 3,3' DIFLUORO 4' METHOXY [1,1' BIPHENYL] 4 CARBOXAMIDE; N [3 (1H INDOL 3 YL) 1 OXO 1 (PYRIDIN 4 YLAMINO)PROPAN 2 YL] 3,3' DIFLUORO [1,1' BIPHENYL] 4 CARBOXAMIDE; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHAGAS DISEASE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MICROSOME; MOUSE; MYOBLAST; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TRYPANOSOMA CRUZI;

14-ALPHA DEMETHYLASE INHIBITORS; AMINOPYRIDINES; ANIMALS; CRYSTALLOGRAPHY, X-RAY; HUMANS; INDOLES; MICE; MICROSOMES, LIVER; MOLECULAR DOCKING SIMULATION; RATS; STEREOISOMERISM; STEROL 14-DEMETHYLASE; STRUCTURE-ACTIVITY RELATIONSHIP; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMA CRUZI;

EID: 84885667273     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401067s     Document Type: Article

References (42)

1. Bern, C. Antitrypanosomal therapy for chronic Chagas' disease N. Engl. J. Med. 2011, 364, 2527-2534
2. Bern, C.; Kjos, S.; Yabsley, M. J.; Montgomery, S. P. Trypanosoma cruzi and Chagas' Disease in the United States Clin. Microbiol. Rev. 2011, 24, 655-681
3. Rassi, A., Jr.; Rassi, A.; Marin-Neto, J. A. Chagas disease Lancet 2010, 375, 1388-1402
4. Rossi, M. A.; Tanowitz, H. B.; Malvestio, L. M.; Celes, M. R.; Campos, E. C.; Blefari, V.; Prado, C. M. Coronary microvascular disease in chronic Chagas cardiomyopathy including an overview on history, pathology, and other proposed pathogenic mechanisms PLoS Neglected Trop. Dis. 2010, 4 e674
5. Chagas, C. Nova trypanozomiaze humana: Estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem Mem. Inst. Oswaldo Cruz 1909, 1, 159-218
6. Apt, W. Current and developing therapeutic agents in the treatment of Chagas disease Drug Des. Dev. Ther. 2010, 4, 243-253
7. Guedes, P. M.; Silva, G. K.; Gutierrez, F. R.; Silva, J. S. Current status of Chagas disease chemotherapy Expert Rev. Anti-Infect. Ther. 2011, 9, 609-620
8. Rassi, A., Jr.; Dias, J. C.; Marin-Neto, J. A.; Rassi, A. Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease Heart 2009, 95, 524-534
9. Buckner, F. S. Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections Adv. Exp. Med. Biol. 2008, 625, 61-80
10. Lepesheva, G. I.; Waterman, M. R. Sterol 14α-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis Curr. Top. Med. Chem. 2011, 11, 2060-2071
11. Kathiravan, M. K.; Salake, A. B.; Chothe, A. S.; Dudhe, P. B.; Watode, R. P.; Mukta, M. S.; Gadhwe, S. The biology and chemistry of antifungal agents: A review Bioorg. Med. Chem. 2012, 20, 5678-5698
12. Lepesheva, G. I.; Ott, R. D.; Hargrove, T. Y.; Kleshchenko, Y. Y.; Schuster, I.; Nes, W. D.; Hill, G. C.; Villalta, F.; Waterman, M. R. Sterol 14α-demethylase as a potential target for antitrypanosomal therapy: Enzyme inhibition and parasite cell growth Chem. Biol. 2007, 14, 1283-1293
13. Urbina, J. A.; Payares, G.; Sanoja, C.; Molina, J.; Lira, R.; Brener, Z.; Romanha, A. J. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains Int. J. Antimicrob. Agents 2003, 21, 39-48
14. Buckner, F. S.; Urbina, J. A. Recent developments in sterol 14-demethylase inhibitors for Chagas Disease Int. J. Parasitol.: Drugs Drug Resist. 2012, 2, 236-242
15. Clayton, J. Chagas disease: Pushing through the pipeline Nature 2010, 465, S12-S15
16. Kraus, J. M.; Tatipaka, H. B.; McGuffin, S. A.; Chennamaneni, N. K.; Karimi, M.; Arif, J.; Verlinde, C. L.; Buckner, F. S.; Gelb, M. H. Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery J. Med. Chem. 2010, 53, 3887-3898
17. Kraus, J. M.; Verlinde, C. L.; Karimi, M.; Lepesheva, G. I.; Gelb, M. H.; Buckner, F. S. Rational modification of a candidate cancer drug for use against Chagas disease J. Med. Chem. 2009, 52, 1639-1647
18. Andriani, G.; Amata, E.; Beatty, J.; Clements, Z.; Coffey, B. J.; Courtemanche, G.; Devine, W.; Erath, J.; Juda, C. E.; Wawrzak, Z.; Wood, J. T.; Lepesheva, G. I.; Rodriguez, A.; Pollastri, M. P. Antitrypanosomal Lead Discovery: Identification of a Ligand-Efficient Inhibitor of Trypanosoma cruzi CYP51 and Parasite Growth J. Med. Chem. 2013, 56, 2556-2567
19. Chen, C.-K.; Leung, S. S. F.; Guilbert, C.; Jacobson, M. P.; McKerrow, J. H.; Podust, L. M. Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole PLoS Neglected Trop. Dis. 2010, 4 e651
20. Lepesheva, G. I.; Hargrove, T. Y.; Anderson, S.; Kleshchenko, Y.; Furtak, V.; Wawrzak, Z.; Villalta, F.; Waterman, M. R. Structural insights into inhibition of sterol 14α-demethylase in the human pathogen Trypanosoma cruzi J. Biochem. 2010, 285, 25582-25590
21. Buckner, F. S.; Wilson, A. J.; White, T. C.; Van Voorhis, W. C. Induction of resistance to azole drugs in Trypanosoma cruzi Antimicrob. Agents Chemother. 1998, 42, 3245-3250
22. Kanafani, Z. A.; Perfect, J. R. Antimicrobial resistance: Resistance to antifungal agents: Mechanisms and clinical impact Clin. Infect. Dis. 2008, 46, 120-128
23. Chen, C. K.; Doyle, P. S.; Yermalitskaya, L. V.; Mackey, Z. B.; Ang, K. K. H.; McKerrow, J. H.; Podust, L. M. Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit PLoS Neglected Trop. Dis. 2009, 3 e372
24. Podust, L. M.; von Kries, J. P.; Eddine, A. N.; Kim, Y.; Yermalitskaya, L. V.; Kuehne, R.; Ouellet, H.; Warrier, T.; Altekoster, M.; Lee, J. S.; Rademann, J.; Oschkinat, H.; Kaufmann, S. H.; Waterman, M. R. Small-molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography Antimicrob. Agents Chemother. 2007, 51, 3915-3923
25. Doyle, P. S.; Chen, C. K.; Johnston, J. B.; Hopkins, S. D.; Leung, S. S.; Jacobson, M. P.; Engel, J. C.; McKerrow, J. H.; Podust, L. M. A non-azole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection Antimicrob. Agents Chemother. 2010, 54, 2480-2488
26. Kumar, S.; Sharma, R.; Roychowdhury, A. Modulation of cytochrome P450 inhibition (CYP) in drug discovery: A medicinal chemistry perspective Curr. Med. Chem. 2012, 19, 3605-3621
27. Gubbins, P. O. Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450 Expert Opin. Drug Metab. Toxicol. 2011, 7, 1411-1429
28. Green, M.; Berman, J. Preparation of pentafluorophenyl esters of Fmoc protected amino acids with pentafluorophenyl trifluoroacetate Tetrahedron Lett. 1990, 31, 5851-5852
29. Choi, J. Y.; Plummer, M. S.; Starr, J.; Desbonnet, C. R.; Soutter, H.; Chang, J.; Miller, J. R.; Dillman, K.; Miller, A. A.; Roush, W. R. Structure guided development of novel thymidine mimetics targeting Pseudomonas aeruginosa thymidylate kinase: From hit to lead generation J. Med. Chem. 2012, 55, 852-870
30. Ross, D. The role of metabolism and specific metabolites in benzene-induced toxicity: Evidence and issues J. Toxicol. Environ. Health A 2000, 61, 357-372
31. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes J. Med. Chem. 2006, 49, 6177-6196
32. Testino, S. A., Jr.; Patonay, G. High-throughput inhibition screening of major human cytochrome P450 enzymes using an in vitro cocktail and liquid chromatography-tandem mass spectrometry J. Pharm. Biomed. Anal. 2003, 30, 1459-1467
33. Gunatilleke, S. S.; Calvet, C. M.; Johnston, J. B.; Chen, C.-K.; Erenburg, G.; Gut, J.; Engel, J. C.; Ang, K. K. H.; Mulvaney, J.; Chen, S.; Arkin, M. R.; McKerrow, J. H.; Podust, L. M. Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51 PLoS Neglected Trop. Dis. 2012, 6 e1736
34. Morrison, J. F. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors Biochim. Biophys. Acta 1969, 185, 269-286
35. Engel, J. C.; Ang, K. K. H.; Chen, S.; Arkin, M. R.; McKerrow, J. H.; Doyle, P. S. Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' Disease Antimicrob. Agents Chemother. 2010, 54, 3326-3334
36. Leslie, A. G. W. Recent changes to the MOSFLM package for processing film and image plate data Joint CCP4 ESF-EAMCB Newslett. Protein Crystallogr. 1992, 26
37. Holton, J.; Alber, T. Automated protein crystal structure determination using ELVES Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 1537-1542
38. Emsley, P.; Cowtan, K. Coot: Model-building tools for molecular graphics Acta Crystallogr., Sect. D 2004, 60, 2126-2132
39. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D 1997, 53, 240-255
40. Collaborative Computational Project, Number 4. Acta Crysallogr., Sect. D 1994, 50, 760-763
41. DeLano, W. L. The PyMOL Molecular Graphics System; DeLano Scientific: San Carlos, CA, 2002.
42. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera: A visualization system for exploratory research and analysis J. Comput. Chem. 2004, 25, 1605-1612